Lysosomal Disorders
The CGTLive™ Lysosomal Disorders specialty topic page contains video interviews with key opinion leaders discussing the most relevant FDA actions, clinical guideline updates, and clinical trial findings related to cell therapies, gene therapies, and engineered and regenerative medicines developed for Lysosomal storage diseases. It also houses the most up-to-date clinical news coverage in the field of gene and cell therapy for diseases related to lysosomal storage and dysfunction.
Latest News
July 26th 2024
The company acquired the program, along with Spark Therapeutics’ pipeline, in December 2019.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30)
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Community Practice Connections™: Multidisciplinary Strategies for Improving Outcomes in CML from Frontline Care… and Beyond!
View More
Oncology Briefings™: Coordinating the Long-Term Management of Patients With Multiple Myeloma Between Primary Care and Oncology Practices
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Oncology Consultations®: Community and Academic Perspectives on PNH Management – How Do You Do It?
View More
Cases and Conversations™: Applying Guidelines to Practice for the Management of Paroxysmal Nocturnal Hemoglobinuria
View More
Oncology Briefings™: Case Discussions in Smoldering Myeloma—To Treat or Not to Treat?
View More
Community Practice Connections™: How Can We Optimize the Real World Application of BCMA-Targeted Therapies for Our Patients with R/R Multiple Myeloma?
View More
Medical Crossfire®: How Has the Nurse’s Role Evolved in the Management of Pediatric Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas?
View More
Oncology Briefings™: Selecting Therapy for Patients with Heavily Pretreated Myeloma Based on Patient and Disease-Specific Factors
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego
View More
Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
View More
Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
View More
Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
View More
Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
View More
How Do We Treat GVHD Today…And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease
View More
Putting Your Stamp on the Next Generation of Care in CML — Improving Outcomes from Frontline to R/R Treatment Settings
View More
Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care
View More
29th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 27 - March 2, 2025
Register Now!
ACCC 50th Annual Meeting Pre-Session: Clinical Updates from San Diego on Hematologic Malignancies
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
28th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
View More
